Results from a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor, in Subjects with Advanced Solid Tumors or Recurrent Malignant Lymphoma - ArQule

Tuesday, September 1, 2015   https://www.arqule.comPosters and Presentations

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300